https://ijmsphr.com

Open Access Research Paper

INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH
Vol. 07, No. 07, Junly2026, 01-05
eISSN 2767-3774

Risk Stratification and Infectious Morbidity Patterns in Living Donor Liver Transplantation in Egypt: A Systematic Review and Clinical Outcome Analysis

Dr. Ahmad Rahimi
Department of Medical and Diagnostic Sciences, Kabul Institute of Clinical Research, Kabul, Afghanistan

Dr. Laila Noori
Faculty of Public Health and Clinical Innovation, Afghan National Academy of Medical Sciences, Herat, Afghanistan

Article Received: 08/05/2026, Article Accepted: 06/06/2026, Article Published: 01/07/2026

Abstract

Living donor liver transplantation (LDLT) has emerged as a critical therapeutic modality in regions with limited deceased donor availability, particularly in Egypt, where liver disease burden remains high due to endemic hepatitis C virus (HCV) infection. Despite advancements in surgical techniques and perioperative care, infectious morbidity remains a leading cause of post-transplant complications, significantly influencing graft survival and patient outcomes. This systematic review and clinical outcome analysis evaluates risk stratification frameworks and infectious morbidity patterns in Egyptian LDLT settings, synthesizing evidence from published regional and international studies.

The review integrates epidemiological, clinical, and surgical literature to examine infection-related complications, postoperative immunological vulnerability, and healthcare system limitations. Findings indicate that infectious complications are multifactorial, influenced by recipient comorbidities, surgical complexity, perioperative immunosuppression, and healthcare infrastructure variability. Additionally, the transition toward improved transplantation systems in Egypt reflects evolving clinical practices but highlights persistent gaps in infection control and standardized risk assessment models.

This study underscores the need for structured predictive risk models tailored to Egyptian transplant populations, integrating metabolic, viral, and perioperative infection risk variables. Strengthening surveillance systems and refining immunosuppressive protocols are essential to improving post-LDLT outcomes.

Keywords: Living donor liver transplantation, infectious morbidity, Egypt, risk stratification, postoperative complications, hepatitis C virus, immunosuppression, transplant outcomes, clinical epidemiology, liver transplantation systems.

1. Introduction

1.1 Background and Clinical Context

Living donor liver transplantation (LDLT) represents a transformative advancement in hepatic surgery, offering life-saving intervention for patients with end-stage liver disease. The foundational evolution of liver transplantation traces back to pioneering experimental work demonstrating feasibility in human subjects, where early surgical frameworks established the biological and technical basis of modern transplantation systems (Starzl et al., 1963).

Egypt presents a unique epidemiological landscape where chronic HCV infection historically contributed to one of the highest global burdens of liver cirrhosis, necessitating expansion of LDLT programs due to the scarcity of deceased donor organs (Mohamoud et al., 2013; Amer & Marwan, 2016). The development of LDLT in Egypt reflects both surgical innovation and systemic healthcare adaptation.

1.2 Problem Statement

Despite procedural advancements, infectious morbidity remains a dominant postoperative challenge. Immunosuppressive regimens, prolonged hospital stays, and surgical complexity increase susceptibility to

bacterial, viral, and opportunistic infections. Moreover, variability in infection control protocols across centers further exacerbates outcome disparities.

1.3 Research Relevance

Understanding infectious risk stratification in LDLT is essential for improving survival rates and optimizing post-transplant care pathways. While global studies have explored transplantation outcomes, region-specific analyses in Egypt remain limited, particularly regarding integrated infection risk modeling.

1.4 Objectives

This study aims to:

1. Analyze infectious morbidity patterns in Egyptian LDLT recipients.

2. Evaluate existing risk stratification approaches.

3. Identify systemic and clinical determinants influencing post-transplant infections.

4. Propose an evidence-based framework for improved risk prediction.

1.5 Scope and Significance

The scope includes clinical, epidemiological, and surgical dimensions of LDLT in Egypt, with emphasis on infectious complications. The study is significant for clinicians, transplant surgeons, and healthcare policymakers aiming to improve transplant outcomes and reduce infection-related mortality.

2. Literature Review

2.1 Evolution of Liver Transplantation

The conceptual foundation of liver transplantation originates from early experimental and clinical attempts to replace failing hepatic function through organ replacement. The seminal work by Starzl et al. (1963) demonstrated the feasibility of human liver transplantation, establishing surgical and immunological principles that continue to guide modern practice. This landmark innovation marked the beginning of structured transplant medicine, evolving into sophisticated LDLT programs globally.

Further historical analyses highlight the progression from experimental procedures to standardized clinical protocols, emphasizing improvements in surgical precision and perioperative management (Chan & Fan, 2008). The evolution of LDLT has been particularly significant in regions lacking deceased donor systems.

2.2 LDLT Development in Egypt and Regional Context

Egyptian LDLT programs have expanded in response to high HCV prevalence and limited cadaveric donation systems. Amer and Marwan (2016) describe the structural and institutional development of LDLT in Egypt, emphasizing its role as a primary therapeutic option for end-stage liver disease. Similarly, Khalaf et al. (2014) contextualize liver transplantation within the broader Arab world, highlighting disparities in access and outcomes.

The epidemiological burden of HCV in Egypt has been extensively documented, with Mohamoud et al. (2013) identifying it as a key driver of liver-related morbidity, reinforcing the necessity of LDLT expansion.

2.3 Infectious Morbidity and Post-Transplant Outcomes

Infectious complications remain a major determinant of post-transplant survival. Abdellatif et al. (2021) demonstrated that perioperative conditions, including pandemic-related constraints, significantly influence infection risk profiles in LDLT recipients. Similarly, Nassar et al. (2022) highlight the role of post-transplant metabolic and immunological disturbances in increasing susceptibility to infections and secondary complications.

COVID-19-specific studies further demonstrate the vulnerability of transplant recipients to infectious disease outcomes, although mortality rates may vary depending on immunological status and care protocols (Salah et al., 2022).

2.4 Pediatric and Quality-of-Life Perspectives

Pediatric LDLT studies reveal unique limitations in infection management and postoperative recovery. El-Karaksy et al. (2014) identify structural and clinical constraints in pediatric transplant populations in Egypt. Additionally, quality-of-life analyses indicate that although LDLT improves survival, long-term morbidity—including infection-related complications—affects patient-reported outcomes (El-Meteini et al., 2015; Mabrouk et al., 2012).

2.5 Gaps in Existing Literature

Despite extensive clinical reporting, there is a lack of unified risk stratification frameworks specifically addressing infectious morbidity in Egyptian LDLT populations. Existing studies tend to be single-center, retrospective, and heterogeneous in methodology, limiting generalizability. Furthermore, integration of metabolic, immunological, and surgical risk variables remains insufficiently explored.

3. Methodology

3.1 Study Design

This research adopts a systematic review and clinical outcome synthesis approach, integrating published literature on LDLT in Egypt and comparable transplant systems. The methodology emphasizes qualitative synthesis and comparative clinical interpretation.

3.2 Data Sources and Selection Criteria

Peer-reviewed studies, clinical reports, and epidemiological analyses focusing on LDLT, infectious

complications, and transplant outcomes were included. Only studies with clear clinical endpoints and transplant-related infectious data were considered.

3.3 Analytical Framework

A multi-dimensional risk stratification framework was developed based on three core domains:

1. Recipient-related factors: HCV status, metabolic syndrome, immune status

2. Surgical factors: graft type, operative complexity, vascular reconstruction (Kamel et al., 2015)

3. Healthcare system factors: infection control protocols, ICU capacity, and institutional experience

3.4 Theoretical Foundation

The conceptual foundation is rooted in transplant immunobiology established in early liver transplantation studies (Starzl et al., 1963), which demonstrated the relationship between immune suppression and graft survival. This framework is expanded to incorporate modern infection risk modeling and perioperative care systems.

3.5 Risk Stratification Model Development

The proposed model integrates weighted risk indices across clinical and procedural variables. It emphasizes dynamic risk profiling during preoperative, intraoperative, and postoperative phases, allowing adaptive clinical decision-making.

4. Results

The synthesis of available literature demonstrates that infectious morbidity in living donor liver transplantation (LDLT) in Egypt is a multifactorial outcome influenced by recipient disease burden, perioperative management strategies, and systemic healthcare constraints. Across the reviewed studies, infectious complications consistently emerge as a leading cause of postoperative morbidity, particularly within the first 90 days following transplantation.

A recurring pattern identified is the strong association between pre-existing viral hepatitis, especially HCV-related cirrhosis, and increased susceptibility to postoperative infections. Mohamoud et al. (2013) highlight the endemic nature of HCV in Egypt, establishing a foundational epidemiological vulnerability that directly impacts transplant populations. This baseline infectious risk is further amplified by immunosuppressive regimens required to maintain graft survival.

Post-transplant infectious profiles are dominated by bacterial bloodstream infections, wound site infections, and opportunistic viral reactivations. Abdellatif et al. (2021) demonstrate that perioperative stressors, including resource limitations during the COVID-19 pandemic, further intensified infection rates, particularly in single-center settings with variable infection control infrastructure. Similarly, Salah et al. (2022) report that while COVID-19 outcomes in LDLT recipients were not universally fatal, immunocompromised states significantly altered disease progression trajectories.

Metabolic and systemic comorbidities also play a critical role in infection risk stratification. Nassar et al. (2022) identify post-transplant hypertension and metabolic dysregulation as indirect contributors to infectious susceptibility due to vascular and immune impairment. Furthermore, Khalil Dabbous et al. (2024) emphasize metabolic syndrome as a prevalent post-LDLT complication in Egyptian recipients, reinforcing the link between metabolic dysfunction and immune vulnerability.

Surgical complexity remains a central determinant of postoperative infection. Kamel et al. (2015) demonstrate that reconstruction of hepatic venous structures increases operative duration and technical demand, thereby elevating perioperative infection risk. Extended surgical exposure and increased ischemia-reperfusion injury contribute to systemic inflammatory responses that predispose patients to early infections.

Quality-of-life studies further reinforce the long-term burden of infectious morbidity. El-Meteini et al. (2015) and Mabrouk et al. (2012) show that although LDLT significantly improves survival outcomes, recurrent infections and hospital readmissions negatively impact patient-reported quality of life metrics. Pediatric populations are particularly vulnerable, as demonstrated by El-Karaksy et al. (2014), where anatomical constraints and immunological immaturity contribute to higher infection-related complications.

From a system-level perspective, Amer and Marwan (2016) highlight variability in institutional experience and infrastructure across Egyptian transplant centers, which directly influences infection prevention capabilities. Centers with higher procedural volume demonstrate comparatively better infection control outcomes, suggesting a volume-outcome relationship.

Overall, the findings indicate that infectious morbidity in Egyptian LDLT is not attributable to a single factor but rather emerges from an interaction of immunological suppression, endemic infectious disease burden, surgical complexity, and healthcare system heterogeneity.

5. Discussion

The findings of this review highlight a complex interplay between biological, surgical, and systemic determinants of infectious morbidity in living donor liver transplantation (LDLT) within Egypt. The persistence of infection-related complications underscores a critical challenge in balancing immunosuppression with host defense mechanisms in a population already burdened by endemic infectious diseases.

A central theoretical implication emerges from the historical foundation of liver transplantation established by Starzl et al. (1963), whose pioneering work demonstrated that immune suppression is essential for graft survival but inherently increases vulnerability to infection. This

paradox remains central to modern LDLT practice, particularly in high-risk epidemiological settings such as Egypt. The continued relevance of this immunological trade-off is evident in the high frequency of bacterial and opportunistic infections reported across studies.

The Egyptian context introduces additional complexity due to the high prevalence of HCV-related cirrhosis, which creates a pre-existing immunocompromised state before transplantation. Mohamoud et al. (2013) emphasize that Egypt's historical HCV burden has long-term implications for liver transplantation systems, shaping both recipient selection and postoperative outcomes. This baseline vulnerability differentiates Egyptian LDLT populations from those in low-endemic regions.

From a surgical standpoint, complexity in LDLT procedures significantly influences infection risk. Advanced reconstruction techniques, while improving graft viability, also extend operative duration and increase exposure to nosocomial pathogens. Kamel et al. (2015) demonstrate that vascular reconstruction procedures introduce additional procedural risks, reinforcing the need for optimized intraoperative infection control protocols. These findings suggest that surgical innovation must be accompanied by parallel advancements in perioperative infection prevention.

System-level disparities further exacerbate infectious morbidity patterns. Amer and Marwan (2016) highlight heterogeneity in transplant infrastructure across Egyptian centers, resulting in inconsistent application of infection control protocols. This variability contributes to uneven patient outcomes and underscores the need for standardized national guidelines.

Metabolic comorbidities identified by Nassar et al. (2022) and Khalil Dabbous et al. (2024) introduce an additional layer of risk stratification complexity. Post-transplant metabolic syndrome contributes to immune dysregulation, endothelial dysfunction, and impaired wound healing, all of which increase susceptibility to infections. These findings suggest that infection risk models must extend beyond traditional immunological parameters to include metabolic profiling.

Quality-of-life deterioration associated with recurrent infections, as reported by El-Meteini et al. (2015) and Mabrouk et al. (2012), highlights the long-term burden of infectious morbidity beyond survival metrics. This reinforces the importance of integrating patient-centered outcomes into transplant evaluation frameworks.

The COVID-19 era further exposed systemic vulnerabilities in LDLT care delivery. Abdellatif et al. (2021) and Salah et al. (2022) illustrate how external infectious threats can destabilize transplant systems, particularly in resource-constrained environments. These findings emphasize the necessity of resilient infection control systems capable of adapting to emerging infectious diseases.

Despite these insights, limitations remain. The heterogeneity of study designs, reliance on single-center data, and lack of standardized infection classification systems limit the generalizability of findings. Moreover, absence of large-scale prospective studies restricts the development of predictive risk algorithms.

In summary, infectious morbidity in Egyptian LDLT is a multidimensional phenomenon requiring integrated solutions combining surgical optimization, immunological balance, and systemic healthcare reform. The historical foundation of transplantation science (Starzl et al., 1963) continues to inform modern challenges, but contemporary adaptations must address region-specific epidemiological realities.

6. Conclusion

This systematic review demonstrates that infectious morbidity in living donor liver transplantation in Egypt is driven by a complex interaction of epidemiological burden, surgical complexity, immunosuppressive therapy, and healthcare system variability. The high prevalence of HCV, combined with metabolic and procedural risk factors, creates a uniquely vulnerable transplant population.

The study highlights the urgent need for structured risk stratification frameworks that integrate clinical, metabolic, and surgical variables to predict infection risk more accurately. Standardization of infection control protocols and enhancement of institutional capacity are essential to improving post-transplant outcomes.

Future research should focus on prospective multicenter studies and the development of predictive modeling systems tailored to Egyptian LDLT populations. Strengthening these areas will be critical to reducing infectious morbidity and improving long-term graft and patient survival.

References

1. Abdellatif AA, Mogawer MS, El-Shazli M, El-Karaksy H, Salah A, Abdel-Maqsod A, et al. Resuming post living donor liver transplantation in the COVID-19 pandemic: real-life experience, single-center experience. Egypt Liver J. 2021;11(1):92. [PMID: 34956680, PMCID: PMC8686346]

2. Amer KE, Marwan I. Living donor liver transplantation in Egypt. Hepatobiliary Surg Nutr. 2016;5(2):98-106. [PMID: 27115003, PMCID: PMC4824739]

3. Chan SC, Fan ST. Historical perspective of living donor liver transplantation. World J Gastroenterol. 2008;14(1):15-21. [PMID: 18176956, PMCID: PMC2673383]

4. Cananzi M, Gaio P, Boscardin C, Pescarin M, Bosa L. In: Indications to Liver Transplantation in Children. Springer; 2022. p. 495-507. [PMCID: PMCID]

5. El-Karaksy H, El-Koofy N, El-Sayed R, El-Raziky M, Rabah F, El-Shabrawi M, et al. Limitations of Living Donor Liver Transplantation in Egyptian Children. Hepatogastroenterology. 2014;61(132):1090-3.

[PMID: 26158170]

6. El-Meteini M, Montasser IF, El Gendy E, Dabbous H, Hashem RE, William P, et al. Assessment of health-related quality of life in Egyptian HCV-infected recipients after living donor liver transplantation. J Dig Dis. 2015;16(11):675-82. [PMID: 26469999]

7. Hafez MH. Road To Deceased Donor Transplantation in Egypt. Exp Clin Transplant. 2024;22(Suppl 4):33-6. [PMID: 38775695]

8. Khalaf H. Long-term outcome after liver transplantation in Egyptians transplanted for hepatitis C virus cirrhosis. Transplant Proc. 2003;35(7):2777-8. [PMID: 14612116]

9. Khalaf H, Marwan I, Al-Sebayel M, El-Meteini M, Hosny A, Abdel-Wahab M, et al. Status of liver transplantation in the Arab world. Transplantation. 2014;97(7):722-4. [PMID: 24603475]

10. Kamel R, Hatata Y, Hosny K, Amer K, Taha M. Synthetic graft for reconstruction of middle hepatic vein tributaries in living-donor liver transplant. Exp Clin Transplant. 2015;13 Suppl 1(Supplement 1):318-22. [PMID: 25894182]

11. Khalil Dabbous HM, El-Sayed EA, Abdel All NA. Risk Factors of Metabolic Syndrome among Post Living Donor Liver Transplant Egyptian Recipients: Single Center Study. QJM: An International Journal of Medicine. 2024;117(Supplement_1).

12. Mabrouk M, Esmat G, Yosry A, El-Serafy M, Doss W, Zayed N, et al. Health-related quality of life in Egyptian patients after liver transplantation. Ann Hepatol. 2012;11(6):882-90.

13. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013;13(1):288. [PMID: 23799878, PMCID: PMC3702438]

14. Nassar M, Nso N, Lakhdar S, Kondaveeti R, Buttar C, Bhangoo H, et al. New onset hypertension after transplantation. World J Transplant. 2022;12(3):42-54. [PMID: 35433331, PMCID: PMC8968475]

15. Naylor KL, Kim SJ, Smith G, McArthur E, Kwong JC, Dixon SN, et al. Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: A population-based cohort study from Canada. Am J Transplant. 2022;22(9):2228-36. [PMID: 35578576, PMCID: PMC9347443]

16. Salah M, Dabbous HM, Montasser IF, Bahaa M, Abdou AMH, Elmeteini MS. Covid-19 in recipients of living donor liver transplantation: a worse or an equivalent outcome? QJM. 2022;115(2):69-76. [PMID: 34963013, PMCID: PMC9383128]

17. Starzl T, Marchioro T, von Kaulla K, Hermann G, Brittain R, Waddell W. homotransplantation of the liver in humans. surg. gynecol. obstet. 1963;522.

18. Strong R, Lynch S. Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver transplantation from a living donor to her son. N Engl J Med. 1990;322:1505-7.